Speaker Profile

Ph.D., Vice President, Head of Science, Oncology, Labcorp

Biography
Taylor Jensen joined Sequenom in 2009 and was part of the team that developed and launched the first commercially available noninvasive prenatal test based on cell-free DNA in the U.S. Subsequently, Dr. Jensen was involved in numerous development efforts focused on the detection of genomic and epigenomic changes in cfDNA for use in prenatal and cancer diagnostics. Since the acquisition of Sequenom by LabCorp in 2016, his work has been primarily focused on biomarkers, precision medicine diagnostic assays, and product strategy with the overarching goal of utilizing these technologies to improve human health. He is a member of multiple professional societies including AACR and ASCO, has contributed to multiple awarded patents, and has authored or co-authored more than 35 publications in peer reviewed scientific journals. He holds a Ph.D. in Pharmacology and Toxicology from the University of Arizona and was a postdoctoral fellow at the Arizona Cancer Center.


Clinical Dx Showcase:
Labcorp

Through unparalleled diagnostics and drug development capabilities, Labcorp provides insights and accelerate innovations to improve health and improve lives.

Personalized Cancer Care-The Role of Somatic and Germline NGS Test
Cancer is a disease of the genome with aberrations derived from both somatic and germline origins; therefore, a comprehensive genetic assessment of the tumor may be optimal to guide treatment, prognosis, and future risk for a patient and their family.

 Session Abstract – PMWC 2024 Silicon Valley

Showcase Track S2 - January 24 9.30 A.M.-1.45 P.M.,Showcase Track S2 - January 25 9.00 A.M.-4.15 P.M.,Showcase Track S2 - January 26 9.00 A.M.-2.45 P.M.


The PMWC 2024 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.

  • Clinical Dx/Oncology (including Liquid Biopsy)
  • Clinical Dx/Cardio Vascular
  • Clinical Dx/Neurodegenerative

×

Add Names/PO on Receipt

Apply to Speak at PMWC Silicon Valley by JUL. 18TH

The PMWC team will reply back to a suitable company/topic with an official request for talk/speaker details.

Contact Us:

Fields marked with an * are required 

Contact Us:

Fields marked with an * are required 

Discover What's Next in Precision Medicine!

Join our community today for the latest news, exclusive interviews, and unique insights from world-renowned speakers and experts


Contact Us:

Fields marked with an * are required 

Discount also depends on group size. The bigger group – the bigger discount.

Trouble Registering

Fields marked with an * are required

Stay Tuned For More Information.

Sign up for occasional updates on upcoming conferences, news, and other information. 

Get Updates:

Submit to Speak in the PMWC Showcase

Fields marked with an * are required